Analysis of the efficacy and adverse reaction of albumin paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer patients
Objective To discuss the efficacy and untoward reaction of albumin paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer(AOC)patients.Methods AOC patients admitted to Nanping First Hospital from Apr 2020 to Mar 2023 were selected and randomly divided into the observation group(treated with albumin paclitaxel com-bined with carboplatin)and the control group(treated with paclitaxel combined with carboplatin)using the random number table method.All the AOC patients were treated for 6 consecutive cycles.Researchers recorded the efficacy,tumor size,tu-mor markers,tumor angiogenesis factors,immune-related factors before and after treatment,and adverse reactions during treatment,and conducted statistical analysis.Results A total of 122 patients were included,61 cases in the observation group and 61 cases in the control group.The total effective rate of the observation group was higher than that of the control group(86.89%vs 65.57%),and the difference was statistically significant(P<0.05).After 6 cycles of treatment,the levels of se-rum HE4,CA125,CA199,VEGF,MMP-9,SDF-1α,IL-10,and IL-17 of the observation group were lower than those of the control group,and the levels of serum IFN-γ was lower than that of the control group,with significant differences(P<0.05).The total incidence of adverse reaction of the observation group was lower than that of the control group(32.79%vs 59.12%),the difference was statistically significant(P<0.05).Conclusion Albumin bound paclitaxel combined with carbopl-atin shows a good effect in the treatment of AOC,which can improve the levels of tumor markers,tumor angiogenesis factors,and immune-related factors with mild adverse reactions.
albumin paclitaxelcarboplatinadvanced ovarian cancerefficacyadverse reaction
NETL
NSTL
万方数据
